Metformin for Knee Osteoarthritis in Patients With Overweight or Obesity
JAMA · 27.05.2025 · 333 (20) · 1804
DOI: 10.1001/jama.2025.3471 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift JAMA, erschienen am 27.05.2025. Verfasst von Feng Pan und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Metformin, Obesity, Osteoarthritis, Knee, Overweight. Die Arbeit wurde bisher 91-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Preclinical and preliminary human evidence suggests that metformin, a first-line treatment for type 2 diabetes, reduces inflammation, preserves cartilage, and improves knee pain in knee osteoarthritis.
Objective
To evaluate the effects of metformin on knee pain at 6 months in participants with symptomatic knee osteoarthritis and overweight or obesity. Design, Setting, and Participants Community-based randomized, parallel-group, double-blind, placebo-controlled clinical trial that used telemedicine to recruit and follow up participants remotely. Individuals with knee pain for 6 months or longer, a pain score greater than 40 mm on a 100-mm visual analog scale (VAS), and body mass index of 25 or higher were recruited from the community through local and social media advertisements in Victoria, Australia, between June 16, 2021, and August 1, 2023. Final follow-up occurred on February 8, 2024.
Interventions
Participants were randomly assigned to receive either oral metformin, 2000 mg/d (n = 54), or identical placebo (n = 53) for 6 months. Main Outcomes and Measures The primary outcome was change in knee pain, measured using a 100-mm VAS (score range, 0-100; 100 = worst; minimum clinically important difference = 15) at 6 months.
Results
Of 225 participants assessed for eligibility, 107 (48%) were randomized (mean age, 58.8 [SD, 9.5] years; 68% female) and assigned to receive metformin or placebo. Eighty-eight participants (82%) completed the trial. At 6 months, the mean change in VAS pain was −31.3 mm in the metformin group and −18.9 mm in the placebo group (between-group difference, −11.4 mm; 95% CI, −20.1 to −2.6 mm; P = .01), corresponding to an effect size (standardized mean difference) of 0.43 (95% CI, 0.02-0.83). The most common adverse events were diarrhea (8 [15%] in the metformin group and 4 [8%] in the placebo group) and abdominal discomfort (7 [13%] in the metformin group and 5 [9%] in the placebo group). Conclusions and Relevance These results support use of metformin for treatment of symptomatic knee osteoarthritis in people with overweight or obesity. Because of the modest sample size, confirmation in a larger clinical trial is warranted. Trial Registration ANZCTR Identifier: ACTRN12621000710820
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
- Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.
- Department of Rheumatology, Alfred Hospital, Melbourne, Victoria, Australia.
Zitieren
APA
Pan, F., Wang, Y., Lim, Y. Z., Urquhart, D. M., Estee, M. M., Wluka, A. E., Wolfe, R., & Cicuttini, F. M. (2025). Metformin for Knee Osteoarthritis in Patients With Overweight or Obesity. JAMA, 333(20), 1804. https://doi.org/10.1001/jama.2025.3471
Vancouver
Pan F, Wang Y, Lim YZ, Urquhart DM, Estee MM, Wluka AE, et al. Metformin for Knee Osteoarthritis in Patients With Overweight or Obesity. JAMA. 2025;333(20):1804. doi:10.1001/jama.2025.3471
BibTeX
@article{Pan2025,
author = {Pan, Feng and Wang, Yuanyuan and Lim, Yuan Z and Urquhart, Donna M and Estee, Mahnuma Mahfuz and Wluka, Anita E and Wolfe, Rory and Cicuttini, Flavia M},
title = {Metformin for Knee Osteoarthritis in Patients With Overweight or Obesity},
journal = {JAMA},
year = {2025},
volume = {333},
number = {20},
pages = {1804},
doi = {10.1001/jama.2025.3471}
}
EUVIMED